Nordea Investment Management’s Coherus Oncology CHRS Stock Holding History

Nordea Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-388,047	Closed	-$2.77M	–	967
2022 Q2	$2.77M	Buy	388,047 +25,849	+7%	+$225K	﹤0.01%	649
2022 Q1	$4.78M	Buy	362,198 +10,419	+3%	+$132K	0.01%	596
2021 Q4	$5.9M	Buy	351,779 +1,472	+0.4%	+$25.7K	0.01%	555
2021 Q3	$5.75M	Sell	350,307 -6,995	-2%	-$103K	0.01%	581
2021 Q2	$4.94M	Buy	357,302 +57,385	+19%	+$813K	0.01%	614
2021 Q1	$4.34M	Sell	299,917 -6,528	-2%	-$111K	0.01%	608
2020 Q4	$5.33M	Buy	306,445 +25,098	+9%	+$447K	0.01%	568
2020 Q3	$5.18M	Sell	281,347 -275,605	-49%	-$5.13M	0.01%	452
2020 Q2	$9.64M	Buy	556,952 +277,514	+99%	+$4.7M	0.01%	453
2020 Q1	$4.68M	Buy	279,438 +9,621	+4%	+$178K	0.01%	433
2019 Q4	$4.82M	Buy	+269,817	New	+$4.98M	0.01%	533

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nordea Investment Management's CHRS Position: Q3 2022 in Review

Nordea Investment Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 388,047 shares — an estimated $2.77M sold.

Nordea Investment Management first reported a position in CHRS in Q4 2019 and held it in 11 quarters. The position peaked at $9.64M in Q2 2020. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

Nordea Investment Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
Nordea Investment Management sold 388,047 Coherus Oncology shares in Q3 2022, an estimated $2.77M.
Nordea Investment Management first reported a position in Coherus Oncology in Q4 2019 and held it in 11 quarters.
Nordea Investment Management's Coherus Oncology position peaked at $9.64M in Q2 2020.
174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Nordea Investment Management's 13F filing for Q3 2022, filed 19 Oct 2022.